Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Johnson & Johnson Q4 Profit Decreases
Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
Johnson & Johnson unveiled financial results that beat Wall Street expectations as the company braces for one of its top-selling medicines, Stelara, to go off patent in the coming weeks.Fourth-quarter sales,
Johnson & Johnson Tops Q4 EPS Forecasts
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Johnson & Johnson Q4 Profit Decreases, But Beats Estimates
Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The
US FDA approves new nasal spray for depression treatment
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.
Ben Johnson takes a jab at Matt LaFleur
Ben Johnson takes a jab at Matt LaFleur during introductory news conference
Bears head coach Ben Johnson makes a joke about beating Packers coach Matt LaFleur twice a season.
New Bears coach Ben Johnson takes dig at Matt LaFleur in introductory press conference
It didn't take new Chicago Bears coach Ben Johnson long to take a not-so-subtle dig at the Green Bay Packers. More specifically, the head coach of the Green Bay Packers. During his introductory press conference with the Bears on Wednesday,
Ben Johnson takes dig at Packers coach Matt LaFleur
Ben Johnson had his choice of several jobs. He chose the Bears. Not only do they have a quarterback to build around, but Johnson also noted they are in a division with which he is familiar. Johnson spent six seasons in the NFC North as an assistant under Dan Campbell.
Bears officially announce Ben Johnson
Brad Biggs: Guided by self-awareness, Ben Johnson is finally prepared for his role as head coach of the Bears
Ben Johnson launched into his virtual interview with the Chicago Bears leaving no question as to his intentions. “I want this job,” Johnson said, Chairman George McCaskey recalled. The feeling was mutual and the Bears agreed to terms with Johnson on Monday.
Chicago Bears' Ben Johnson becomes one of youngest head coaches in NFL. See where he ranks
The Bears introduce Ben Johnson as new head coach, continuing a trend started with Sean McVay. Johnson isn't the youngest in the NFL, but he's close.
With Ben Johnson on the move to Chicago, 5 head coaching vacancies remain
Ben Johnson made a quick decision. Aaron Glenn could be next. With Johnson heading to Chicago and Mike Vrabel already in New England, five head coaching vacancies remain. The Jets, Saints, Jaguars, Raiders and Cowboys are still in the hunt.
21h
Johnson & Johnson says positioned for 5%-7% growth through 2030 and beyond
Says starting 2025 from a position of strength. Says invested ~$50B in R&D and M&A in 2024. Says continues to invest in R&D at ...
MassDevice
23h
Johnson & Johnson MedTech sales grow 6.2% in 2025, driven by EP, Abiomed
Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...
23h
on MSN
Johnson & Johnson posts Q4 beat as drug sales offset MedTech weakness
Johnson & Johnson (JNJ) traded flat after exceeding Street forecasts with its Q4 2024 results thanks mainly to its Innovative ...
1d
Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
MarketBeat on MSN
5d
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
Johnson & Johnson (NYSE: JNJ) stock is up 1.8% in the five days after the company announced its $14.6 billion acquisition of ...
6d
on MSN
Mike Johnson has a new headache in the narrowly divided House: From the Politics Desk
Johnson sent shockwaves around Capitol Hill when he decided to oust Rep. Mike Turner, R-Ohio — a staunch NATO supporter who ...
6d
Hold Rating for Johnson & Johnson Amid Modest Growth Outlook and Legal Uncertainties
In a report released today, Tim Anderson from Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research ...
6d
Johnson Installs Crawford on Intelligence Panel, Pulling It Closer to Trump
The speaker replaced a Republican who had criticized the president-elect and broken with him on key issues, and who had drawn ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback